Jim O'Neill says he spends sleepless nights worrying whether his Review of Antimicrobial Resistance (AMR) will run out of steam once completed in two months' time - but he's encouraged by growing evidence world leaders and the pharma industry are seriously embracing the theme and will soon make lasting commitments to effectively combat antibiotic resistance, including in Asia.
Lord O'Neill of Gatley says the G20 and the United Nations are gradually moving to address the acute need for the dozen or so new antibiotic drugs he believes are needed globally, along with preventative action to curb AMR, importantly including in China.
O'Neill - ex-chair of Goldman Sachs Asset Management and the man appointed by UK Prime Minister David Cameron to launch...
After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.
Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.
A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease, which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing.
Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.
The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.
As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.
The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.
